Podcasts about transcatheter aortic valve replacement

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Drs. Michael Mack and Tom Nguyen about the proposed US Centers for Medicare & Medicaid Services changes to how cardiologists and cardiac surgeons interact during transcatheter aortic valve replacement (TAVR) procedures. Chapters 00:00 Intro 01:21 TAVR Heart Team 04:08 JANS 1+2, JACC TAVR vs SAVR 12:19 JANS 3, TAVR Short-Term Outcomes 14:06 JANS 4, SAVR Life Expectancy 17:44 JANS 5, WSJ TAVR Article 19:19 Video 1, Direct AA Cannulation Technique 21:23 Video 2, Endoscopic Redo TVR After CABG 24:25 Video 3, Gaudiani Cox-Maze III 27:33 Dr. Mack & Nguyen, TAVR Heart Team 51:12 Closing Dr. Mack explained the current heart team system, established in 2011 through collaboration with the US Food and Drug Administration (FDA) and CMS, which has been highly successful in ensuring safe and effective TAVR implementation. He argues that the proposed CMS changes could potentially dismantle this collaborative approach by allowing asynchronous patient evaluation and procedures to be performed by single operators without surgeon involvement. Dr. Nguyen provided insights from a system leader's perspective, noting that while the proposed changes raise significant concerns about patient care and data collection, some cardiologists argue that surgeons are already not actively involved in many programs, making the single operator model the norm in practice. Both expressed concern that without mandatory surgeon participation and TAVR registry involvement, smaller programs may adopt practices that lack proper accountability and could lead to inappropriate patient selection and outcomes, potentially creating more contentious debates between TAVR and surgical approaches. Joel also highlights recent JANS articles including a propensity-matched analysis comparing 10-year outcomes after SAPIEN 3 TAVR in the PARTNER 2 SAPIEN 3 Intermediate-risk Registry with surgery in the PARTNER 2A trial; a single-center retrospective study evaluated 61 patients who underwent cardiac surgery after prior TAVR during a 10-year period at a high-volume academic center; whether surgical aortic valve replacement (SAVR) should remain the first choice for aortic stenosis in patients with a life expectancy beyond five years; and an article examining the dramatic rise in the popularity of transcatheter aortic valves, early valve failure, and the impact it has on patients' lives. In addition, Joel explores axillary cannulation as a primary cannulation strategy, beating-heart endoscopic tricuspid valve replacement for high-risk redo patients after CABG and device-related tricuspid valve injury, and a Cox-Maze III operation combined with a left internal mammary artery (LIMA) to left anterior descending artery (LAD), as well as an ascending aortic replacement and aortic valve resuspension. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned 10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients A Decade of Cardiac Surgery After Transcatheter Aortic Valve Replacement: Short-Term Clinical Outcomes at a High-Volume Center Great Debate: Surgical Aortic Valve Replacement Is First Choice for Aortic Stenosis in Patients With a Life Expectancy Beyond 5 Years A Breakthrough Heart Procedure Comes With Risky Tradeoffs CTSNet Content Mentioned Direct Axillary Artery Cannulation With the Open Seldinger Technique Endoscopic Redo Tricuspid Valve Replacement After CABG The Cox-Maze III Procedure Combined With Valve-Sparing Aortic Surgery and CABG Other Items Mentioned Centers for Medicare & Medicaid Services Database—TAVR Career Center CTSNet Events   Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251413753

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Mark Tuttle.

Commentary by Dr. Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Send us a textSt. Luke's introduced TAVR – catheter-based replacement of the aortic valve – to Cedar Rapids, performing the area's first procedure in 2016. Since then, the heart team has performed nearly 800 TAVRs. Joining the podcast to talk about the procedure are Dr. Richard Kettelkamp and Katie Maybanks, ACNP, from St. Luke's structural cardiology team. To learn more about heart care services at St. Luke's, Cedar Rapids' Heart Hospital, visit unitypoint.org/cr-heart. Do you have a question about a trending medical topic? Ask Dr. Arnold! Submit your question and it may be answered by Dr. Arnold on the podcast! Submit your questions at: https://www.unitypoint.org/cedarrapids/submit-a-question-for-the-mailbag.aspxIf you have a topic you'd like Dr. Arnold to discuss with a guest on the podcast, shoot us an email at stlukescr@unitypoint.org.

Commentary by Dr.  Jian'an Wang.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251386377

Interview with Alfred E. Buxton, MD, and Marie-France Poulin, MD, authors of Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement. Hosted by Kristen K. Patton, MD. Related Content: Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement

Interview with Alfred E. Buxton, MD, and Marie-France Poulin, MD, authors of Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement. Hosted by Kristen K. Patton, MD. Related Content: Mechanisms Underlying Alterations in Cardiac Conduction After Transcatheter Aortic Valve Replacement

Commentary by Dr.  Jian'an Wang.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Predictors of Length-of-Stay Among Transcatheter Aortic Valve Replacement Patients Using a Supervised Machine Learning Algorithm.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251325568

Commentary by Dr. Jian'an Wang.

Transcatheter Aortic Valve Replacement With Self-expanding Valves Vs. Balloon-expandable Valves - A Pooled Analysis From Navultra And Neopro2 Registries

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Patrick Badertscher, MD, discuss analysis from SWISS-TAVI registry regarding long-term outcomes of patients requiring pacemaker implantation after TAVI.

The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I  FDA announces approval for TAVR in pts with asymptomatic AS Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 II PPG that Can Distinguish source of Tachycardia Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798 III PRAETORIAN -XL trial Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576 Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932 Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917 The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156 IV Stroke in Young People Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855 Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Transcatheter Aortic Valve Replacement for Failing Bioprosthetic Surgical Valves: Five-Year Outcomes of the Partner 3 Aortic Valve-in-Valve Registry

In this podcast, Dr. Valentin Fuster presents a comprehensive review of conduction disturbances following transcatheter aortic valve replacement (TAVR), highlighting key factors that contribute to the need for permanent pacemaker implantation. The discussion covers current management strategies, risks, and future perspectives, emphasizing the need for improved prediction methods and the evolving role of ambulatory monitoring and physiological pacing techniques.

Electrosurgical Leaflet Modification to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement in Failing Native and Bioprosthetic Valves: The TELLTALE Trial

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on The Impact of Frailty on VARC-3 Integrated Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

The field of transcatheter aortic valve replacement (TAVR) continues to evolve, with new research expanding its indications and refining its application. This JACC special issue brings together cutting-edge studies, meta-analyses, and expert perspectives on key topics shaping the future of TAVR. Highlights include pivotal trials assessing TAVR in low-risk patients, a growing focus on moderate aortic stenosis and heart failure, and novel insights into reintervention strategies. The issue also presents comprehensive analyses on asymptomatic severe aortic stenosis, valve durability, and patient selection for next-generation TAVR applications. As TAVR increasingly moves beyond its initial role in high-risk patients, the studies featured here provide essential data to guide clinical decision-making, optimize outcomes, and address the challenges of valve longevity, structural durability, and patient-centric approaches. We hope this collection informs and inspires continued innovation in structural heart disease management.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

Welcome to a special re-run of Doc Talk! Today, we're revisiting Episode 30—Time for TAVR with Dr. Joseph Tuma—just in time for Heart Valve Disease Awareness Day, happening February 21st from 4 to 6 PM at Monument Health Rapid City Hospital.TAVR, or Transcatheter Aortic Valve Replacement, is a groundbreaking procedure for those with aortic valve disease. If you or someone you love is at risk, this episode is a must-listen. Hosted on Acast. See acast.com/privacy for more information.

Commentary by Dr.  Jian'an Wang

Abdullah Al-Abcha, MD, social media editor of JACC: Cardiovascular Interventions, and Thomas Pilgrim, MD, MSc, discuss a recently published manuscript reporting the incidence, predictors, and clinical outcomes hemodynamic valve deterioration after transcatheter aortic valve replacement.

Drs Harrington and Gibson review their picks for the top cardiology trials of 2024 and look ahead to 2025, particularly what health topics may be prioritized by the new administration. This podcast is intended for healthcare professionals only. To read a transcript or to comment https://www.medscape.com/author/bob-harrington Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (REDUCE AMI) https://www.nejm.org/doi/abs/10.1056/NEJMoa2401479 Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD) https://doi.org/10.1056/nejmoa2412006 Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis EARLY TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 Asundexian versus Apixaban in Patients with Atrial Fibrillation (OCEANIC-AF) https://doi.org/10.1056/NEJMoa2407105 In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat? https://www.jacc.org/doi/10.1016/j.jacc.2024.10.105 Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial https://doi.org/10.1016/S0140-6736(24)00413-6 Preventive Coronary Stents: Not There Yet https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr Speech by Commissioner Robert M. Califf to the House of Medicine June 16, 2023 https://www.fda.gov/news-events/speeches-fda-officials/speech-commissioner-robert-m-califf-house-medicine-06162023 Evolution of Single-Lead ECG for STEMI Detection Using a Deep Learning Approach https://doi.org/10.1016/j.ijcard.2021.11.039 From ST-Segment Elevation MI to Occlusion MI: The New Paradigm Shift in Acute Myocardial Infarction https://doi.org/10.1016/j.jacadv.2024.101314 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Co-STAR: Colchicine in Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial

TAVR UNLOAD: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning discusses the latest salaries and conditions of cardiothoracic surgeons in the United States. He explores the highest versus lowest compensation areas, areas with the highest growth for compensation, and where cardiothoracic surgeons rank among other surgeons. He also highlights the highest paid specialties, burnout rates, early retirement, and noncompete clauses.   Joel also reviews recent JANS articles on transcatheter aortic valve replacement for asymptomatic severe aortic stenosis, transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis, valve-in-valve transcatheter aortic valve replacement versus isolated redo surgical aortic valve replacement, and the seven pillars of techniques to treat and repair tricuspid endocarditis.  In addition, Joel explores surgical aortic annulus enlargement using a balloon technique, quadruple valve replacement for carcinoid heart disease, and Fontan conversion in a patient with hypoplastic left heart syndrome. Before closing, he highlights upcoming events in CT surgery. JANS Items Mentioned  1.) Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis—EARLY TAVR Trial  2.) Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD  3.) Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Isolated Redo Surgical Aortic Valve Replacement  4.) The Seven Pillars of Techniques to Treat and Repair Tricuspid Endocarditis  CTSNET Content Mentioned  1.) Surgical Aortic Annulus Enlargement Using a Balloon Technique  2.) Quadruple Valve Replacement for Carcinoid Heart Disease  3.) Fontan Conversion in a Patient With Hypoplastic Left Heart Syndrome: A 38-Year-Old Norwood Saga  Other Items Mentioned  1.) Doximity Pay Report 2023   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this episode of Structural Heart Talks, Larry Wood, Corporate VP and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, discusses the transformative journey of transcatheter aortic valve replacement (TAVR) and the SAPIEN valve. Wood reflects on the innovation that enables minimally invasive heart valve replacement, which has become the standard of care for severe aortic stenosis and offers patients faster recovery and greater independence. The conversation explores Edwards' efforts to expand access to TAVR, emphasizing the importance of reducing undertreatment and addressing outdated clinical guidelines that delay intervention. Wood also highlights findings from the recent early TAVR study, which challenges long-standing paradigms and advocates for changes to the guidelines to allow earlier treatment of aortic stenosis before symptoms appear. Thank you to Confluent Medical Technologies for sponsoring this episode of Structural Heart Talks. To learn more about how Confluent Medical supports medical device companies, visit: www.confluentmedical.com. Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

In this episode of the JACC: Asia podcast, Cheol Hyun Lee explores the prognostic impact of patient-prosthesis mismatch (PPM) following transcatheter aortic valve replacement (TAVR) in Asian patients, who tend to have smaller annular sizes compared to Western populations. The study highlights that while severe PPM occurs in only 1.3% of patients, it is significantly linked to a higher risk of heart failure hospitalization, underscoring the need for personalized treatment approaches in Asia to reduce the risk of severe PPM.

In this podcast, Editor-in-Chief Jian'an Wang discusses the ongoing debate over patient-prosthesis mismatch (PPM) following transcatheter aortic valve replacement (TAVR), highlighting conflicting findings between Western and Asian cohorts. Recent data from the updated Ocean TAVR registry suggests that severe PPM is an independent risk factor for long-term mortality and rehospitalization, underscoring the need for personalized device selection to improve outcomes, particularly in patients with smaller annuli and larger body surface areas.

Author Nicolas M. Van Mieghem, MD, PhD, FACC, and JACC: Executive Associate Editor Aakriti Gupta, MD, FACC,  discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on renin-angiotensin system inhibition in patients with myocardial injury complicating TAVR.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on Machine Learning Identification of Modifiable Predictors of Patient Outcomes After Transcatheter Aortic Valve Replacement

Abdullah Al-Abcha, MD, social media editor of JACC: Cardiovascular Interventions, and Firas Zahr, MD, discuss a recently published original research paper on a study that aimed to assess the impact of tricuspid regurgitation on outcomes of TAVR with balloon expandable valves.

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Toshiki Kuno, MD, PhD, discuss a recently published original research paper examining the comparison of outcomes between leadless (micra) and transvenous pacemakers after TAVR.

Commentary by Dr. Abdullah Al-Abcha and Dr. Tanush Gupta

LATE BREAKING CLINICAL TRIAL: Cost-Effectiveness of Transcatheter Aortic Valve Replacement for Low-Risk Patients – Updated Results from the Evolut Low Risk Trial

Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial

Interview with Jonathan Afilalo, MD, MSc, author of Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement. Hosted by Robert O. Bonow, MD. Related Content: Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement

Interview with Jonathan Afilalo, MD, MSc, author of Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement. Hosted by Robert O. Bonow, MD. Related Content: Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement

Surgical Aortic Valve Replacement with Contemporary Valves Versus Self-Expanding Transcatheter Aortic Valve Replacement: 4-Year Outcomes from the Evolut Low Risk Trial

Commentary by Dr. Valentin Fuster

Stroke is a potentially devastating TAVR complication. In this episode, CardioNerds (Drs. Amit Goyal, Nikolaos Spilias, Ahmed Ghoneem, and Chelsea Amo-Tweneboah) discuss TAVR and stroke risk, stroke prevention strategies, and future directions with Dr. Samir Kapadia, Department chair and chief, Cardiovascular Medicine at Cleveland Clinic. They also discuss device innovation and randomized controlled trial implementation for testing device safety and efficacy. Audio editing by CardioNerds Academy Intern, Dr. Chelsea Amo Tweneboah. As an adjunct to this episode and for a deeper review of cerebral embolic protection devices, read “Cerebral Embolic Protection Devices: Current State of the Art” by Agrawal, Kapadia et al., in US Cardiology Review. CardioNerds Aortic Stenosis SeriesCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - TAVR and Stroke Leon MB, Smith CR, Mack M, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010;363(17):1597-1607. Kapadia SR, Makkar R, Leon M, et al. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. New England Journal of Medicine. 2022;387(14):1253-1263. Kapadia SR, Kodali S, Makkar R, et al. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology. 2017;69(4):367-377. Khan MZ, Zahid S, Khan MU, et al. Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: A US nationwide study. Catheter Cardiovasc Interv. 2021;98(5):959-968.

Exercise, sudden cardiac death in sports, new TAVI data, behavioral psychology, EHR doing good things, maybe, and coffee are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Fitness and Longevity Even Small Changes in Fitness Tied to Lower Mortality Risk https://www.medscape.com/viewarticle/989906 - Changes in Cardiorespiratory Fitness and Survival in Patients With or Without Cardiovascular Disease https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.027 II. SCD in Sports Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women https://www.medscape.com/viewarticle/990025 - Incidence of Cardiac Arrest During Sports Among Women in the European Union https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.015 - Sex-Related Differences in Sports-Related Sudden Cardiac Death Should Be Reflected in Guideline Screening Recommendations∗   https://www.jacc.org/doi/full/10.1016/j.jacc.2023.01.014 - Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort https://doi.org/10.1093/eurheartj/ehz897 III. EVOLUT Three Year Data Encouraging 3-Year Data for TAVR in Low-Risk Patients: EVOLUT https://www.medscape.com/viewarticle/989144 - Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 - Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients https://www.nejm.org/doi/full/10.1056/nejmoa1816885 - Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk https://www.jacc.org/doi/10.1016/j.jacc.2020.12.052 IV. Behavioral Psychology NUDGE-FLU: Electronic 'Nudges' Boost Flu Shot Uptake in Seniors https://www.medscape.com/viewarticle/989108 - The Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: a Prespecified Analysis of the NUDGE-FLU Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064270 - Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.121.057042 EHR Alerts Boosted MRA Prescribing in HFrEF: BETTER CARE-HF https://www.medscape.com/viewarticle/989110 - Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care https://doi.org/10.1016/j.jacc.2023.02.005 - The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure https://www.nejm.org/doi/full/10.1056/nejm199909023411001 V. Coffee - Acute Effects of Coffee Consumption on Health among Ambulatory Adults https://www.nejm.org/doi/full/10.1056/NEJMoa2204737 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net